Fast Market Research

New Market Research Report: Dr. Falk Pharma GmbH - Product Pipeline Review - 2013

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 02/06/2014 -- Global Market Direct's pharmaceuticals report, "Dr. Falk Pharma GmbH - Product Pipeline Review - 2013" provides data on the Dr. Falk Pharma GmbH's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, Dr. Falk Pharma GmbH's corporate website, SEC filings, investor presentations and featured press releases, both from Dr. Falk Pharma GmbH and industry-specific third party sources, put together by Global Markets Direct's team.


- Dr. Falk Pharma GmbH - Brief Dr. Falk Pharma GmbH overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Dr. Falk Pharma GmbH human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Dr. Falk Pharma GmbH with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Dr. Falk Pharma GmbH's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

View Full Report Details and Table of Contents

Reasons to Get This Report

- Evaluate Dr. Falk Pharma GmbH's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Dr. Falk Pharma GmbH in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Dr. Falk Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Dr. Falk Pharma GmbH.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Dr. Falk Pharma GmbH and identify potential opportunities in those areas.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PARI Pharma GmbH - Product Pipeline Review - 2013
- CellAct Pharma GmbH - Product Pipeline Review - 2013
- Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2013
- Grunenthal GmbH - Product Pipeline Review - 2013
- Ulcerative Colitis - Pipeline Review, H2 2013
- Primary Biliary Cirrhosis - Pipeline Review, H2 2013
- Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2013
- Dr. Falk Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Transplantation - Pipeline Review, H2 2013
- Alzheimer's Disease - Pipeline Review, H2 2013